About AtheroNova... there is a reason to their madness. The company wants to go public on the NYSE. To do so, they need to trade at or above $3.00 a share for at least 30 out of 60 days. This is a very small pharmaceutical company. But they have patented and developed a compound, which should be a huge success. They are currently very much below Wall Street's radar. They have only about 160 investors, my self included. Most of the shares are held by their top executives. Anyone who understands this company will not sell any shares. The small amount of trading of this stock are penny traders. The company has finished FDA phase I and phase II testing, with very good results. If you understand FDA testing, the next phase III involves prescribing the drug to about 3000 patients, while monitoring them very closely for results or problems. Phase III testing is about to begin, or may have already begun. Phase III testing should finished in Q4 of 2014.
This company wants to be trading on the NYSE when phase III results are released. This is a very safe compound. FDA approval should soon follow, and should be no problem. Please, do you own due diligence.
Sorry if I seem to be hyping this stock. If you think I'm out of line, just say so. If you're interested, I found some links to some video presentations made about two years ago by Mr. Gardner, the CEO of AtheroNova, back when he was trying to raise money to keep the research moving forward.
Jim from Michigan.
News 
Market Data 
Discover 
